Literature DB >> 11522709

Advanced glycation end products in nondiabetic patients with coronary artery disease.

M Kanauchi1, N Tsujimoto, T Hashimoto.   

Abstract

OBJECTIVE: To investigate whether advanced glycation end products (AGEs) participate in the development of coronary artery disease (CAD) in nondiabetic and diabetic subjects. RESEARCH DESIGN AND METHODS: Serum concentrations of AGEs were measured using a newly established enzyme-linked immunosorbent assay in 48 nondiabetic patients (normal glucose tolerance, n = 20; impaired glucose tolerance, n = 28) who received coronary angiography for the study of chest pain or suspected CAD. Insulin sensitivity was examined by the euglycemic-hyperinsulinemic glucose clamp technique and was estimated as the mean glucose infusion rate during the last 30 min of clamp time (M value).
RESULTS: Patients were classified into four groups based on the number of significantly stenosed vessels, defined as 0-, 1-, 2-, or 3-vessel disease. Serum concentrations of AGEs were significantly higher in nondiabetic subjects with CAD than in control subjects (2.42 +/- 0.65 vs. 1.96 +/- 0.40 mU/ml, P < 0.01) and significantly correlated with the number of significantly stenosed vessels (r = 0.678, P < 0.001). M values significantly inversely correlated with serum concentrations of AGEs (r = -0.490, P < 0.05). In multiple regression analysis, with the number of significantly stenosed vessels as the dependent variable, serum concentrations of AGEs, 2-h plasma glucose, and areas under the plasma glucose response curve were independently associated.
CONCLUSIONS: This pilot study indicates the relation between AGEs and the severity of CAD in nondiabetic patients. The measurement of serum AGE concentrations may be predictive of vascular damage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522709     DOI: 10.2337/diacare.24.9.1620

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  27 in total

Review 1.  Does accumulation of advanced glycation end products contribute to the aging phenotype?

Authors:  Richard D Semba; Emily J Nicklett; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-17       Impact factor: 6.053

2.  Post-challenge hyperinsulinaemia rather than hyperglycaemia is associated with the severity of coronary artery disease in patients without a previous diagnosis of diabetes mellitus.

Authors:  H Satoh; H Terada; A Uehara; H Katoh; M Matsunaga; K Yamazaki; F Matoh; H Hayashi
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

Review 3.  Advanced glycation end products and vascular structure and function.

Authors:  Georgia Soldatos; Mark Emmanuel Cooper
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

4.  Comparison of Periodontal Ligament Cell Lines with Adenovirus- and Lentivirus-Mediated Human Telomerase Reverse Transcription Expression.

Authors:  Guijun Sun; Yang Yang; Xiaoyan Lu; Qing Liu; Shengrong Wu; Jiajia Jin; Zixiao Huang; Xiangyi He
Journal:  Hum Gene Ther Methods       Date:  2019-02-28       Impact factor: 2.396

5.  Association between carotid diameter and the advanced glycation end product N-epsilon-carboxymethyllysine (CML).

Authors:  Marcus Baumann; Tom Richart; Daniel Sollinger; Jaroslav Pelisek; Marcel Roos; Tatiana Kouznetsova; Hans-Henning Eckstein; Uwe Heemann; Jan A Staessen
Journal:  Cardiovasc Diabetol       Date:  2009-08-06       Impact factor: 9.951

6.  Beneficial effects of losartan on vascular injury induced by advanced glycosylation end products and their receptors in spontaneous hypertension rats.

Authors:  Wei-Wei Zhu; Xue-Ping Liu; Nan Wu; Ting-Ting Zhao; Yong Zhao; Jie Zhang; Jian-Hua Shao
Journal:  Mol Cell Biochem       Date:  2007-05-09       Impact factor: 3.396

7.  Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events.

Authors:  D J Mulder; P L van Haelst; R Graaff; R O Gans; F Zijlstra; A J Smit
Journal:  Neth Heart J       Date:  2009-04       Impact factor: 2.380

8.  Advanced glycation end-products in senile diabetic and non-diabetic patients with cardiovascular complications.

Authors:  Anjuman Gul; M Ataur Rahman; Asmat Salim; Shabana U Simjee
Journal:  Age (Dordr)       Date:  2008-09-03

9.  Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy.

Authors:  Se-Jung Yoon; Young Won Yoon; Byoung Kwon Lee; Hyuck Moon Kwon; Ki-Chul Hwang; Myunghyun Kim; Woochul Chang; Bum-Kee Hong; Young-Ho Lee; Soon-Jung Park; Pil-Ki Min; Se-Joong Rim
Journal:  Exp Mol Med       Date:  2009-11-30       Impact factor: 8.718

Review 10.  Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality.

Authors:  Kailash Prasad
Journal:  Int J Angiol       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.